For the quarter ending 2026-03-31, OTLK made $127,439 in revenue. -$4,453,081 in net income. Net profit margin of -3494.28%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues, net | 127,439 | -1,207,833 | -3,102,431* | 1,505,322 |
| Cost of revenues | 149,327 | 29,626 | 36,885* | 439,815 |
| Gross profit | -21,888 | -1,237,459 | -3,139,316* | 1,065,507 |
| Research and development | 4,500,520 | 3,634,352 | 5,776,522* | 7,134,706 |
| Selling, general and administrative | 9,504,579 | 8,612,141 | 10,899,788* | 9,679,481 |
| Loss from operations | -14,026,987 | -13,483,952 | -19,815,626* | -15,748,680 |
| Loss on equity method investment | -45,119 | -38,634 | -48,355* | -30,884 |
| Interest income | - | - | 22,434.5* | - |
| Interest (income) expense , net | 3 | 0 | -135,075* | -49,351 |
| (loss) gain from change in fair value of promissory notes | -2,495,400 | 6,743,736 | -897,345* | 2,323,977 |
| Warrant inducement expenses (note 10) | - | - | 8,380,468.5* | - |
| Gain from change in fair value of warrant liability | -6,838,022 | 2,791,813 | -25,104,430.75* | 1,999,610 |
| Gain on extinguishment of debt | 285,600 | - | - | - |
| Net loss before income taxes | -4,453,081 | - | -2,355,314.25* | -20,152,502 |
| Income tax (benefit) expense | - | - | -387,957.25* | - |
| Net loss | -4,453,081 | -23,058,135 | -1,967,357 | -20,152,502 |
| Basic EPS | -0.05 | -0.38 | -0.06 | -0.55 |
| Diluted EPS | -0.05 | -0.38 | -0.06 | -0.55 |
| Basic Average Shares | 81,835,900 | 60,205,035 | 32,635,658 | 36,956,582 |
| Diluted Average Shares | 81,835,900 | 60,205,035 | 32,635,658 | 36,956,582 |
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)